Talis Biomedical

Talis Biomedical FCF/Debt

Delisted

The Free Cash Flow to Debt Ratio of Talis Biomedical (TLIS) as of Nov 1, 2026 is -210.21 %. In the previous year, Free Cash Flow to Debt Ratio was -239.13 % — a change of -12.09% (higher).

FCF/Debt

-210.21 %

YoY

-12.09%

Last updated:

Free Cash Flow to Debt Ratio of Talis Biomedical is 2023 -210.21 % . Free Cash Flow to Debt Ratio of Talis Biomedical was 2022 -239.13 % . It decreases by -12.09% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Talis Biomedical Stock analysis

What does Talis Biomedical do? Talis Biomedical Corp develops and commercializes the Talis One system, a cloud-enabled molecular diagnostic platform comprising a compact instrument, single-use test cartridges, and software linked to a central cloud database. The company targets healthcare providers seeking point-of-care molecular testing for infectious diseases, respiratory infections, women's health conditions, and sexually transmitted infections (STIs). Its products include assay kits for respiratory panels combining influenza A, influenza B, and COVID-19 tests, designed for use by untrained personnel. Revenue is generated through sales of the Talis One system and associated assay kits to healthcare facilities requiring rapid, accurate diagnostic solutions. The Talis One system is positioned for central laboratory-level accuracy at the point of care, appealing to clinics and hospitals needing efficient diagnostic tools. The Respiratory Panel, integrating influenza A, influenza B, and COVID-19 assays, addresses high-demand areas in infectious disease testing. The company's focus on women's health and STI-related assays expands its market reach within specialized healthcare segments. Sales of these products are directed toward healthcare providers who prioritize accessible, user-friendly diagnostic technology without requiring extensive training. Talis Biomedical Corp's commercial strategy centers on delivering diagnostic solutions that combine advanced molecular testing with ease of use. The Talis One system and its assay kits are marketed to healthcare facilities aiming to enhance diagnostic capabilities at the point of care. By targeting respiratory infections, women's health, and STIs, the company addresses key areas where rapid, accurate testing is critical. Revenue streams are derived from the sale of both the hardware platform and the consumable test kits, ensuring ongoing customer engagement through recurring purchases. Talis Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Talis Biomedical stock

Free Cash Flow to Debt Ratio of Talis Biomedical is -210.21 % in 2023.

Free Cash Flow to Debt Ratio of Talis Biomedical changed from -239.13 % to -210.21 %, representing a -12.09% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Talis Biomedical since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Talis Biomedical with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Talis Biomedical

All Key Metrics — Talis Biomedical